Physician profile
David Bolos
NPI 1134494321
$2,810.17
in general payments reported to CMS, 2019-2025
34 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $167 · 2021: $52.43 · 2022: $96.10 · 2023: $567 · 2024: $368 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.01 |
| Education | $389.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $300.76 | 2020-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $252.28 | 2019-2023 | Adcetris, Tukysa |
| Janssen Biotech, INC. | $191.53 | 2020-2025 | Imbruvica, Carvykti, Talvey |
| Merck Sharp & Dohme LLC | $169.04 | 2024-2025 | Keytruda, Welireg |
| Amgen INC. | $161.85 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Lilly USA, LLC | $143.72 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Regeneron Healthcare Solutions, INC. | $120.83 | 2019-2025 | Libtayo |
| Pfizer INC. | $114.54 | 2019-2024 | |
| Sobi, INC | $99.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $99.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $95.24 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Genentech USA, INC. | $90.51 | 2023-2025 | Tecentriq, Columvi |
| Incyte Corporation | $87.81 | 2019-2025 | Jakafi |
| Abbvie INC. | $82.17 | 2024-2025 | |
| Adc Therapeutics America, INC. | $80.13 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $74.72 | 2019-2023 | |
| Genzyme Corporation | $69.19 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.56 | 2019-2023 | |
| Eisai INC. | $60.98 | 2019-2025 | |
| Gilead Sciences, INC. | $59.19 | 2025 | Trodelvy |
| Foundation Medicine, INC. | $42.75 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.60 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $33.62 | 2023 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $31.47 | 2019-2020 | |
| Geron Corporation | $31.38 | 2025 | Rytelo |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Tersera Therapeutics LLC | $28.70 | 2023 | Xermelo |
| Kite Pharma, INC. | $28.12 | 2025 | Yescarta |
| Mirati Therapeutics, INC. | $23.61 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $23.59 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $23.19 | 2019 | |
| Array Biopharma INC | $18.36 | 2025 | Braftovi, Lorbrena, Xalkori |
| Agios Pharmaceuticals, INC. | $18.24 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bolos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.